Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia

Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tol...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Lima, Lisa M, Arellano, Martha, Holloway, Stacie, Shepard, Marian, McMillan, Stephanie, Khoury, Hanna Jean
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2010
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3262317/
https://ncbi.nlm.nih.gov/pubmed/22282699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S7158
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares